| Original language | English |
|---|---|
| Pages (from-to) | e106-e116 |
| Journal | The Lancet HIV |
| Volume | 11 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 12 Jan 2024 |
Bibliographical note
Funding Information:The authors thank the study participants for their contribution to the research. The authors acknowledge the contribution of the ACCESS team members and ACCESS advisory committee members who are not coauthors of this article. The authors also acknowledge all clinical services participating in ACCESS. The list of ACCESS team members, advisory committee members, and participating services can be found on the ACCESS website. ACCESS is a partnership between the Burnet Institute, Kirby Institute, and National Reference Laboratory. The ATHENA database is maintained by Stichting HIV Monitoring and supported by a grant from the Dutch Ministry of Health, Welfare and Sport through the Centre for Infectious Disease Control of the National Institute for Public Health and the Environment. The authors acknowledge the contribution of the Swiss HIV Cohort Study (SHCS) participants and team members. This study has been financed within the framework of the SHCS, supported by the Swiss National Science Foundation (grant 201369) and by the SHCS research foundation. Data from the SHCS are gathered by the Five Swiss University Hospitals, two Cantonal Hospitals, 15 affiliated hospitals, and 36 private physicians. The authors would like to thank all clinicians and clinical research technicians participating in the SAIDCC database of the Infectious Diseases Unit of St Antoine Hospital (Paris, France). We acknowledge the contribution of the AQUITAINE scientific committee. We also acknowledge the ANRS CO3 Aquitaine/AquiVIH-NA Cohort participants, the study coordinators, the central coordinating team, and nurses for their assistance with study coordination, participant recruitment, and care. The ANRS CO3 Aquitaine cohort is supported by the ANRS Emerging Infectious Diseases and the Bordeaux University Hospital Centre. The authors acknowledge the CoRIS Executive Committee and the centres and investigators involved in the CoRIS cohort. The CoRIS cohort is supported by CIBER – Consorcio Centro de Investigación Biomédica en Red – (CB21/13/00091), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU. We acknowledge the contribution of the Scientific Committee of the ANRS CO13 HEPAVIH including representatives of the sponsor (clinical research and pharmacovigilance department) and representatives of patient organisations including TRT5. We also acknowledge the ANRS CO13 HEPAVIH cohort participants, the study coordinators, the central coordinating team, and nurses for their assistance with study coordination, participant recruitment, and care. The ANRS CO13 Hepavih cohort is supported by the ANRS Emerging Infectious Diseases. We acknowledge the Canadian Coinfection Cohort (CCC) steering committee members, central coordinating staff, study participants, and community advisers. We also acknowledge Canadian Coinfection Cohort coinvestigators, study coordinators, and nurses for their assistance with study coordination, participant recruitment, and care. The Canadian Coinfection Cohort is supported by Fonds de recherche du Québec-Santé; the Canadian Institute for Health Research (CIHR; FDN-143270); and the CIHR Canadian HIV Trials Network (CTN222). We would also like to acknowledge Campbell Aitken for English language editing of the manuscript text. This study was funded by the Australian Government National Health and Medical Research Council (grant numbers GNT1132902 and GNT2020121). We gratefully acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program received by the Burnet Institute.
Funding Information:
The authors thank the study participants for their contribution to the research. The authors acknowledge the contribution of the ACCESS team members and ACCESS advisory committee members who are not coauthors of this article. The authors also acknowledge all clinical services participating in ACCESS. The list of ACCESS team members, advisory committee members, and participating services can be found on the ACCESS website. ACCESS is a partnership between the Burnet Institute, Kirby Institute, and National Reference Laboratory. The ATHENA database is maintained by Stichting HIV Monitoring and supported by a grant from the Dutch Ministry of Health, Welfare and Sport through the Centre for Infectious Disease Control of the National Institute for Public Health and the Environment. The authors acknowledge the contribution of the Swiss HIV Cohort Study (SHCS) participants and team members . This study has been financed within the framework of the SHCS, supported by the Swiss National Science Foundation (grant 201369) and by the SHCS research foundation. Data from the SHCS are gathered by the Five Swiss University Hospitals, two Cantonal Hospitals, 15 affiliated hospitals, and 36 private physicians. The authors would like to thank all clinicians and clinical research technicians participating in the SAIDCC database of the Infectious Diseases Unit of St Antoine Hospital (Paris, France). We acknowledge the contribution of the AQUITAINE scientific committee. We also acknowledge the ANRS CO3 Aquitaine/AquiVIH-NA Cohort participants, the study coordinators, the central coordinating team, and nurses for their assistance with study coordination, participant recruitment, and care. The ANRS CO3 Aquitaine cohort is supported by the ANRS Emerging Infectious Diseases and the Bordeaux University Hospital Centre. The authors acknowledge the CoRIS Executive Committee and the centres and investigators involved in the CoRIS cohort . The CoRIS cohort is supported by CIBER – Consorcio Centro de Investigación Biomédica en Red – (CB21/13/00091), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU. We acknowledge the contribution of the Scientific Committee of the ANRS CO13 HEPAVIH including representatives of the sponsor (clinical research and pharmacovigilance department) and representatives of patient organisations including TRT5. We also acknowledge the ANRS CO13 HEPAVIH cohort participants, the study coordinators, the central coordinating team, and nurses for their assistance with study coordination, participant recruitment, and care. The ANRS CO13 Hepavih cohort is supported by the ANRS Emerging Infectious Diseases. We acknowledge the Canadian Coinfection Cohort (CCC) steering committee members, central coordinating staff, study participants, and community advisers. We also acknowledge Canadian Coinfection Cohort coinvestigators, study coordinators, and nurses for their assistance with study coordination, participant recruitment, and care. The Canadian Coinfection Cohort is supported by Fonds de recherche du Québec-Santé; the Canadian Institute for Health Research (CIHR; FDN-143270); and the CIHR Canadian HIV Trials Network (CTN222). We would also like to acknowledge Campbell Aitken for English language editing of the manuscript text. This study was funded by the Australian Government National Health and Medical Research Council (grant numbers GNT1132902 and GNT2020121). We gratefully acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program received by the Burnet Institute.
Publisher Copyright:
© 2024 Elsevier Ltd
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver